摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,2,4,6,7-pentamethyl-2,3-dihydro-benzofuran-5-sulfonic acid 1-amino-1-[(S)-4-(naphthalene-2-sulfonylamino)-5-oxo-5-piperazin-1-yl-pentylamino]-meth-(E)-ylideneamide | 1276540-65-8

中文名称
——
中文别名
——
英文名称
2,2,4,6,7-pentamethyl-2,3-dihydro-benzofuran-5-sulfonic acid 1-amino-1-[(S)-4-(naphthalene-2-sulfonylamino)-5-oxo-5-piperazin-1-yl-pentylamino]-meth-(E)-ylideneamide
英文别名
2-[(4S)-4-(naphthalen-2-ylsulfonylamino)-5-oxo-5-piperazin-1-ylpentyl]-1-[(2,2,4,6,7-pentamethyl-3H-1-benzofuran-5-yl)sulfonyl]guanidine
2,2,4,6,7-pentamethyl-2,3-dihydro-benzofuran-5-sulfonic acid 1-amino-1-[(S)-4-(naphthalene-2-sulfonylamino)-5-oxo-5-piperazin-1-yl-pentylamino]-meth-(E)-ylideneamide化学式
CAS
1276540-65-8
化学式
C33H44N6O6S2
mdl
——
分子量
684.881
InChiKey
ASDIOUKTXYESMS-NDEPHWFRSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    47
  • 可旋转键数:
    11
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    189
  • 氢给体数:
    4
  • 氢受体数:
    9

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF<br/>[FR] COMPOSITIONS COMPRENANT DES PROMÉDICAMENTS OPIACÉS CLIVABLES PAR ENZYME ET LEURS INHIBITEURS
    申请人:PHARMACOFORE INC
    公开号:WO2011133149A1
    公开(公告)日:2011-10-27
    The present disclosure provides pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions comprise a prodrug that provides enzymatically-controlled release of a drug and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the drug from the prodrug so as to attenuate enzymatic cleavage of the prodrug. The disclosure provides pharmaceutical compositions which comprise an enzyme inhibitor and a prodrug that contains an enzyme-cleavable moiety that, when cleaved, facilitates release of the drug.
    本公开提供了一种药物组合物及其使用方法,其中所述药物组合物包含一种前药,该前药能够提供通过酶控释放的药物,以及一种酶抑制剂,该酶抑制剂与介导从该前药酶控释放药物的酶相互作用,以减弱前药的酶裂解。本公开还提供了包含酶抑制剂和含酶可裂解基团的前药的药物组合物,所述酶可裂解基团在裂解时有助于药物的释放。
  • [EN] COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF<br/>[FR] COMPOSITIONS COMPRENANT DES PROMÉDICAMENTS CLIVABLES PAR ENZYME DE PRINCIPES ACTIFS ET LEURS INHIBITEURS
    申请人:PHARMACOFORE INC
    公开号:WO2011133150A1
    公开(公告)日:2011-10-27
    The present disclosure provides pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions comprise a prodrug that provides enzymatically-controlled release of a drug and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the drug from the prodrug so as to attenuate enzymatic cleavage of the prodrug. The disclosure provides pharmaceutical compositions which comprise an enzyme inhibitor and a prodrug that contains an enzyme-cleavable moiety that, when cleaved, facilitates release of the drug.
    本公开提供了一种药物组合物及其使用方法,其中所述药物组合物包含一种前药,该前药能够提供通过酶控释放的药物,以及一种酶抑制剂,该酶抑制剂与介导药物从该前药通过酶控释放的酶相互作用,以减弱前药的酶切。本公开还提供了一种包含酶抑制剂和前药的药物组合物,所述前药包含一个酶可切割的部分,切割后可促进药物的释放。
  • COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF
    申请人:Jenkins Thomas E.
    公开号:US20110262355A1
    公开(公告)日:2011-10-27
    Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an opioid prodrug that provides enzymatically-controlled release of an opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the opioid from the opioid prodrug so as to attenuate enzymatic cleavage of the opioid prodrug.
    提供的药物组合物及其使用方法,其中药物组合物包括一种阿片类药物的前药,该前药提供酶控释放的阿片类药物,以及一种酶抑制剂,该酶抑制剂与介导阿片类药物前药酶控释放的酶相互作用,以减弱对阿片类药物前药的酶切。
  • COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF
    申请人:Jenkins Thomas E.
    公开号:US20110262359A1
    公开(公告)日:2011-10-27
    The present disclosure provides pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions comprise a prodrug that provides enzymatically-controlled release of a drug and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the drug from the prodrug so as to attenuate enzymatic cleavage of the prodrug. The disclosure provides pharmaceutical compositions which comprise an enzyme inhibitor and a prodrug that contains an enzyme-cleavable moiety that, when cleaved, facilitates release of the drug.
    本公开提供了药物组合物及其使用方法,其中药物组合物包括一种前药,该前药提供酶控释放药物的能力,以及一种酶抑制剂,与介导前药中药物酶控释放的酶相互作用,以减弱前药的酶解作用。该公开提供了包括酶抑制剂和含有酶可切割基团的前药的药物组合物,当切割时,促进药物释放。
  • Pharmaceutical compositions with attenuated release of phenolic opioids
    申请人:Signature Therapeutics, Inc.
    公开号:US09534014B2
    公开(公告)日:2017-01-03
    Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise a phenolic opioid prodrug that provides enzymatically-controlled release of a phenolic opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the phenolic opioid from the prodrug so as to attenuate enzymatic cleavage of the prodrug.
    提供了药物组合物及其使用方法,其中药物组合物包括一种酚类阿片类前药,提供酶控释放酚类阿片类药物,以及一种酶抑制剂,与介导酚类阿片类前药酶控释放的酶相互作用,以减弱前药的酶解。
查看更多